Biolife Solutions Inc BLFS
We take great care to ensure that the data presented and summarized in this overview for BIOLIFE SOLUTIONS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLFS
View all-
Casdin Capital, LLC New York, NY8.71MShares$232 Million16.93% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$147 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA3.2MShares$85.5 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$76.1 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY1.58MShares$42.1 Million0.2% of portfolio
-
State Street Corp Boston, MA1.41MShares$37.7 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.15MShares$30.7 Million0.07% of portfolio
-
Cramer Rosenthal Mcglynn LLC Greenwich, CT1.1MShares$29.4 Million1.63% of portfolio
-
Geneva Capital Management LLC865KShares$23.1 Million0.37% of portfolio
-
Dimensional Fund Advisors LP Austin, TX847KShares$22.6 Million0.01% of portfolio
Latest Institutional Activity in BLFS
Top Purchases
Top Sells
About BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Insider Transactions at BLFS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 17
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,196
-4.78%
|
$356,292
$27.16 P/Share
|
Dec 16
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,604
-2.68%
|
$205,308
$27.33 P/Share
|
Nov 26
2024
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
216
-0.36%
|
$5,832
$27.2 P/Share
|
Nov 26
2024
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
349
-0.32%
|
$9,423
$27.2 P/Share
|
Nov 26
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
523
-0.18%
|
$14,121
$27.2 P/Share
|
Nov 26
2024
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
581
-0.47%
|
$15,687
$27.2 P/Share
|
Nov 26
2024
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
252
-0.16%
|
$6,804
$27.2 P/Share
|
Nov 18
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
17,604
-5.83%
|
$352,080
$20.05 P/Share
|
Nov 15
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.89%
|
$525,000
$21.17 P/Share
|
Nov 15
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.97%
|
$20,000
$2.06 P/Share
|
Nov 12
2024
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
147
-0.12%
|
$3,822
$26.19 P/Share
|
Nov 12
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
123
-0.04%
|
$3,198
$26.34 P/Share
|
Nov 12
2024
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
66
-0.04%
|
$1,716
$26.34 P/Share
|
Nov 12
2024
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
91
-0.08%
|
$2,366
$26.34 P/Share
|
Oct 30
2024
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
894
-0.72%
|
$20,562
$23.15 P/Share
|
Oct 30
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
547
-0.17%
|
$12,581
$23.15 P/Share
|
Oct 30
2024
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
277
-0.18%
|
$6,371
$23.15 P/Share
|
Oct 30
2024
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
311
-0.29%
|
$7,153
$23.15 P/Share
|
Oct 30
2024
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
203
-0.33%
|
$4,669
$23.15 P/Share
|
Oct 16
2024
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.05%
|
$230,000
$23.17 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 338K shares |
---|---|
Exercise of conversion of derivative security | 50K shares |
Other acquisition or disposition | 150K shares |
Open market or private sale | 229K shares |
---|---|
Other acquisition or disposition | 150K shares |